DEA should remove barriers to opioid use disorder treatment

March 2023

Share this:

BCHC submitted comments to DEA about the proposed rule on the Expansion of Induction of Buprenorphine via Telemedicine Encounter.

BCHC urges DEA to:

  • eliminate the in-person evaluation when prescribing more than a 30-day supply of buprenorphine via telemedicine and to promulgate consistent policies across federal agencies;

  • promulgate a rule to allow prescribing of buprenorphine via telehealth permanently;

  • develop consistency across clinical settings and providers in reporting to prescription drug monitoring programs (PDMPs).

Download PDF 230.5KB

Read the full comment

Download now Read the full comment
Share this: